Investigating how lipid nanoparticles improve mRNA vaccine effectiveness
Lipid nanoparticle adjuvants for mRNA vaccines: composition-function relation and mechanism of action
This study is looking at how tiny particles called lipid nanoparticles can help make mRNA vaccines work better by boosting the immune response, and it's mainly testing this in mice to find out how they help the body fight off infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11133367 on NIH RePORTER |
What this research studies
This research explores the role of lipid nanoparticles (LNPs) as adjuvants in mRNA vaccines, focusing on how different compositions of LNPs can enhance immune responses. By conducting experiments primarily in mice, the researchers aim to understand how these nanoparticles stimulate the immune system to produce antibodies against various pathogens. The study will also investigate the mechanisms by which the immune system recognizes LNPs and how their properties can be optimized for better vaccine performance.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals who are at risk for infectious diseases and may require vaccination.
Not a fit: Patients who are not eligible for vaccination or those with contraindications to mRNA vaccines may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide stronger and longer-lasting immunity against infectious diseases.
How similar studies have performed: Other research has shown promising results with lipid nanoparticles in vaccine development, indicating a strong potential for success in this area.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Pardi, Norbert — University of Pennsylvania
- Study coordinator: Pardi, Norbert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.